Opportunity Information: Apply for PA 06 462
Apply for PA 06 462
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R33)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.273 Alcohol Research Programs 93.279 Drug Abuse and Addiction Research Programs 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 93.866 Aging Research.
- This funding opportunity was created on Dec 5, 2008 and posted on Aug 7, 2006.
- Applicants must submit their applications by Sep 7, 2009 Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- Eligible applicants include: Independent school districts Native American tribal governments (Federally recognized) State governments City or township governments Others (see text field entitled Additional Information on Eligibility for clarification) Public housing authorities/Indian housing authorities Special district governments County governments Private institutions of higher education Public and State controlled institutions of higher education For profit organizations other than small businesses Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith based or community based organizations can apply. Applicant organizations may submit more than one application, provided each application is scientifically distinct.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity PA-06-462, titled "Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R33)," supports Phase II developmental research focused on creating and testing new brain imaging radioligands for use with positron emission tomography (PET) or single photon emission computed tomography (SPECT). It is sponsored by multiple NIH institutes with strong CNS and substance use portfolios, including the National Institute of Mental Health (NIMH), the National Institute on Aging (NIA), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the National Institute on Drug Abuse (NIDA). The central purpose is to move promising imaging ligands closer to real-world usefulness by combining ligand development with early feasibility evaluation, so that resulting tools can function as biomarkers in drug discovery and in studies of brain pathophysiology.
The projects envisioned under this R33 mechanism are aimed at developing novel radiotracers that can image specific targets in the human brain, such as receptors, transporters, enzymes, or other molecular processes relevant to central nervous system disorders. A key expectation is that applications will not stop at chemistry or tracer design alone; they should also incorporate pilot or clinical feasibility evaluation. That evaluation can occur through preclinical studies (for example, proof-of-concept imaging and biodistribution work), model development (such as kinetic modeling approaches that enable quantification of binding and signal), and/or clinical studies that establish whether the ligand can be used practically in humans. In other words, the FOA is oriented toward translational outcomes: radioligands that are not just theoretically interesting, but demonstrably workable as imaging biomarkers.
By emphasizing biomarkers, the announcement highlights how PET and SPECT ligands can de-risk and accelerate therapeutic development. Imaging biomarkers can help show whether a drug engages its intended target in the brain, support dose selection, measure receptor occupancy, and provide objective readouts of biological changes linked to disease mechanisms. At the same time, these tools can be used outside of drug trials to map neurochemical or molecular alterations associated with psychiatric, neurodegenerative, addiction-related, or alcohol-related disorders, helping clarify underlying pathophysiology and potentially supporting patient stratification or treatment-response prediction.
Administratively, this is a discretionary grant program under the NIH with an R33 Funding Instrument (Phase II Developmental). The opportunity lists an award ceiling of $500,000 and indicates there is no cost sharing or matching requirement. The program was posted on August 7, 2006, with multiple receipt dates and a final listed closing date of September 7, 2009, and an archive date of October 7, 2009 (meaning it was time-limited and is now archived as a historical FOA). It is associated with several CFDA numbers spanning mental health, aging, alcohol research, drug abuse research, neuroscience, and related technological innovation areas, reflecting its cross-cutting relevance to CNS research across NIH institutes.
Eligibility is broad and includes many types of domestic applicants, such as state and local governments, tribal governments and tribal organizations, school districts, public housing authorities, special district governments, counties, nonprofits (including both 501(c)(3) and non-501(c)(3) entities), private and public institutions of higher education, and for-profit organizations (including small businesses and for-profits other than small businesses). The FOA also explicitly allows foreign institutions to apply, permits eligible federal agencies to apply, and notes that faith-based and community-based organizations are eligible. Applicants may submit more than one application as long as each is scientifically distinct, which is relevant for institutions with multiple ligand programs or target areas.
The full announcement and official details were made available through the NIH Office of Extramural Research site at the listed link (http://grants.nih.gov/grants/guide/pa-files/PA-06-462.html). For technical issues accessing the announcement, the contact provided is the NIH OER Webmaster (FBOWebmaster@OD.NIH.GOV).
Frequently Asked Questions (FAQs)
What is PA-06-462?
PA-06-462 is an NIH funding opportunity titled "Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R33)." It supports Phase II developmental research focused on developing and testing new brain imaging radioligands for use with PET (positron emission tomography) or SPECT (single photon emission computed tomography).
What is the main goal of this funding opportunity?
The central goal is to move promising PET/SPECT imaging ligands closer to real-world usefulness by combining ligand development with early feasibility evaluation. The intended outcome is radioligands that can function as imaging biomarkers in drug discovery and in studies of brain pathophysiology related to central nervous system (CNS) disorders.
What type of NIH grant mechanism does this opportunity use?
This opportunity uses the NIH R33 mechanism, described as a Phase II Developmental funding instrument.
What kinds of projects are envisioned under the R33 mechanism in this FOA?
Projects are aimed at developing novel radiotracers that can image specific targets or molecular processes in the human brain, such as receptors, transporters, enzymes, or other CNS-relevant molecular processes. A key expectation is that projects include not only ligand development but also early feasibility evaluation.
Does the FOA support work limited to chemistry or tracer design alone?
No. The FOA explicitly indicates that applications should not stop at chemistry or tracer design alone. Projects are expected to incorporate pilot or clinical feasibility evaluation so the ligand is demonstrably workable as an imaging biomarker.
What types of feasibility evaluation are encouraged?
The FOA describes feasibility evaluation that may include preclinical studies (such as proof-of-concept imaging and biodistribution work), model development (including kinetic modeling to quantify binding and signal), and/or clinical studies that test whether the ligand can be used practically in humans.
What imaging modalities are covered by this funding opportunity?
The opportunity is focused on radioligands intended for use with PET or SPECT brain imaging.
What kinds of biological targets can the radioligands image?
The FOA describes targets including receptors, transporters, enzymes, and other molecular processes relevant to CNS disorders.
How are PET and SPECT ligands intended to be used as biomarkers under this FOA?
The announcement emphasizes imaging biomarkers that can support drug discovery (for example, demonstrating target engagement in the brain, supporting dose selection, and measuring receptor occupancy) and that can also be used to study CNS pathophysiology by mapping neurochemical or molecular alterations associated with CNS-related disorders.
Which disease or research areas does this FOA relate to?
Based on the institutes involved and the stated scope, the FOA relates to CNS disorders broadly, including areas aligned with psychiatric research, neurodegenerative research, and substance use and alcohol-related research, as well as studies aimed at understanding brain pathophysiology.
Which NIH institutes sponsor or participate in this opportunity?
The opportunity is sponsored by multiple NIH institutes with strong CNS and substance use portfolios, including the National Institute of Mental Health (NIMH), the National Institute on Aging (NIA), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the National Institute on Drug Abuse (NIDA).
What is the award ceiling listed for this FOA?
The opportunity lists an award ceiling of $500,000.
Is cost sharing or matching required?
No. The FOA indicates there is no cost sharing or matching requirement.
When was this funding opportunity posted?
The program was posted on August 7, 2006.
What were the application receipt dates and closing date?
The FOA states there were multiple receipt dates, with a final listed closing date of September 7, 2009.
Is this FOA still active?
No. The FOA is described as time-limited and is archived. It lists an archive date of October 7, 2009, which indicates it is a historical announcement rather than an active, open opportunity.
Who is eligible to apply?
Eligibility is broad and includes many types of domestic applicants such as state and local governments, tribal governments and tribal organizations, school districts, public housing authorities, special district governments, counties, nonprofits (including 501(c)(3) and non-501(c)(3) entities), private and public institutions of higher education, and for-profit organizations (including small businesses and for-profits other than small businesses).
Are foreign institutions eligible to apply?
Yes. The FOA explicitly allows foreign institutions to apply.
Are federal agencies eligible to apply?
Yes. The FOA notes that eligible federal agencies may apply.
Are faith-based and community-based organizations eligible?
Yes. The FOA states that faith-based and community-based organizations are eligible.
Can an applicant submit more than one application?
Yes. Applicants may submit more than one application as long as each application is scientifically distinct.
Where can the full official announcement be found?
The full announcement is available through the NIH Office of Extramural Research at http://grants.nih.gov/grants/guide/pa-files/PA-06-462.html.
Who should be contacted for technical problems accessing the FOA?
For technical issues accessing the announcement, the contact listed is the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV.
What does it mean that multiple CFDA numbers are associated with this FOA?
The FOA is associated with several CFDA numbers spanning mental health, aging, alcohol research, drug abuse research, neuroscience, and related technological innovation areas. This reflects the cross-cutting relevance of PET/SPECT imaging ligand development across multiple CNS-focused NIH research domains.
What kinds of outcomes is the FOA trying to promote?
The FOA is oriented toward translational outcomes: radioligands that are not only conceptually promising but also supported by early feasibility work showing they can be applied practically as imaging biomarkers for drug discovery and/or CNS pathophysiological studies.
Browse more opportunities from the same category: Education Health
Next opportunity: Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (Phased Innovation Award R21/R33)
Previous opportunity: Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 06 462
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 06 462) also looked into and applied for these:
| Funding Opportunity |
|---|
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (Phased Innovation Award R21/R33) Apply for PA 06 463 Funding Number: PA 06 463 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Dissemination and Implementation Research in Health (R03) Apply for PAR 06 520 Funding Number: PAR 06 520 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Dissemination and Implementation Research in Health (R21) Apply for PAR 06 521 Funding Number: PAR 06 521 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Translational Research for the Prevention and Control of Diabetes and Obesity (R18) Apply for PAR 06 532 Funding Number: PAR 06 532 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Behavioral Science Track Award for Rapid Transition (B/START) (R03) Apply for PAR 06 541 Funding Number: PAR 06 541 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis (R21) Apply for PA 07 022 Funding Number: PA 07 022 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Focal Cognitive Deficits in CNS Disorders (R03) Apply for PA 07 034 Funding Number: PA 07 034 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Focal Cognitive Deficits in CNS Disorders (R21) Apply for PA 07 035 Funding Number: PA 07 035 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Discovery for Nervous System Disorders (R21) Apply for PAR 07 049 Funding Number: PAR 07 049 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Molecular genetics of drug addiction and related co morbidities (R01) Apply for PA 07 073 Funding Number: PA 07 073 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis (R01) Apply for PA 07 021 Funding Number: PA 07 021 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Basic Research in the Bladder and Lower Urinary Tract (R01) Apply for PA 07 023 Funding Number: PA 07 023 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Mechanisms of Alcohol Associated Cancers (R01) Apply for PA 07 069 Funding Number: PA 07 069 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research on Chronic Insomnia Disorder (R01) Apply for PA 07 047 Funding Number: PA 07 047 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Discovery for Nervous System Disorders (R01) Apply for PAR 07 048 Funding Number: PAR 07 048 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research On The Reduction And Prevention Of Suicidality (R01) Apply for PA 07 079 Funding Number: PA 07 079 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Risk Factors For Psychopathology Using Existing Data Sets (R01) Apply for PA 07 082 Funding Number: PA 07 082 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Dissemination and Implementation Research in Health (R01) Apply for PAR 07 086 Funding Number: PAR 07 086 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| HIV Infection Of The Central Nervous System (R01) Apply for PA 07 089 Funding Number: PA 07 089 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| HIV/AIDS, Severe Mental Illness And Homelessness (R01) Apply for PA 07 090 Funding Number: PA 07 090 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 06 462", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.